文献速递炎症性肠病

核糖核酸酶T2基因多态性与克罗恩病严重临床特征及表达降低的关联

Association of Ribonuclease T2 Gene Polymorphisms With Decreased Expression and Clinical Characteristics of Severity in Crohn's Disease.
PubMed 文献 · Gastroenterology · 2017-04-09

研究探讨TL1A调控细胞因子产生的机制及与克罗恩病结局的关联,发现RNASET2是IFNG分泌T细胞中唯一下调超过5倍的IBD风险相关基因,其风险变异与表达降低、DNA高甲基化及更复杂疾病或治疗抵抗相关。

要点

  • RNASET2是IFNG分泌T细胞中唯一下调超过5倍的IBD风险相关基因。
  • RNASET2风险变异与克罗恩病患者更复杂疾病或治疗抵抗相关。
  • RNASET2敲低增加IFNG和ICAM1表达并诱导T细胞聚集。

核心结论

  • RNASET2表达降低是TL1A介导的IFNG产生增加的一个组成部分,并可能是严重克罗恩病患者的潜在生物标志物。

研究设计与样本

  • 外周T细胞来自正常供体,经TL1A刺激后行RNA测序基因表达谱分析。
  • 通过流式细胞术分选干扰素γ(IFNG)产生和非产生细胞亚群,行无监督层次聚类分析。
  • 用数量性状位点分析评估RNASET2表达和甲基化。
  • 将患者临床特征(并发症、治疗抵抗、复发时间)与RNASET2单核苷酸多态性关联。
  • 在CD4+ T细胞中用siRNA敲低RNASET2,通过蛋白质组学分析和细胞因子产生检测效果,流式细胞术测细胞聚集。

主要发现

  • 在TL1A介导的IFNG分泌和非分泌T细胞之间,鉴定出764个基因表达差异至少2倍(P < 1 × 10-5)。
  • RNASET2是唯一在IFNG分泌亚群中下调超过5倍的IBD风险相关基因。
  • RNASET2疾病风险变异与需要手术干预的克罗恩病患者外周和黏膜组织中表达降低及DNA高甲基化相关。
  • RNASET2疾病风险变异与克罗恩病患者更复杂疾病或治疗抵抗相关,部分定义为治疗失败、肠切除长度增加、重复手术时间缩短和术后内镜Rutgeerts评分高(>2)。
  • RNASET2变异rs2149092被预测破坏增强子区域内转录因子ETS的共识结合位点,RNASET2表达与ETS表达相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Variants in the tumor necrosis factor superfamily member 15 gene (TNFSF15, also called TL1A) have been associated with risk for inflammatory bowel disease (IBD). TL1A affects expression of multiple cytokines to promote mucosal inflammation. Little is known about the TL1A-response pathways that regulate cytokine expression. We investigated T-cell gene expression patterns to determine the mechanisms by which TL1A regulates cytokine production, and whether these associate with outcomes of patients with Crohn's disease (CD). METHODS: Peripheral T cells isolated from normal donors were cultured with TL1A. We performed gene expression profile analysis by RNA sequencing of subsets of interferon gamma (IFNG)-producing and non-producing cells purified by flow cytometry. Unsupervised hierarchical clustering analysis was used to identify gene expression differences between these subsets. Ribonuclease T2 gene (RNASET2) expression and methylation were assessed by quantitative trait loci analyses. Clinical characteristics of patients (complications, resistance to therapy, and recurrence time) were associated with single nucleotide polymorphisms in RNASET2. We performed motif screening to identify polymorphisms that disrupt transcription factor binding sites. Levels of RNASET2 were knocked down with small interfering RNA in CD4+ T cells and the effect on protein expression was determined by proteomic analysis and cytokine production. Cell aggregation was measured by flow cytometry. RESULTS: We identified 764 genes with at least a 2-fold difference in TL1A-mediated expression between IFNG-secreting and non-secreting T cells (P < 1 × 10-5). Many of these genes were located near IBD susceptibility variants. RNASET2 was the only IBD risk-associated gene with >5-fold down-regulation in the IFNG-secreting subset. RNASET2 disease risk variants were associated with decreased expression in peripheral and mucosal tissues and DNA hypermethylation in CD patients requiring surgical intervention. RNASET2 disease risk variants were associated in CD patients with more complicated disease or resistance to therapy, defined in part by failed response to treatment, increased length of intestinal resection, shorter time to repeat surgery, and high Rutgeerts score (>2) in postoperative endoscopy. The RNASET2 variant rs2149092 was predicted to disrupt a consensus binding site for the transcription factor ETS within an enhancer region. Expression of RNASET2 correlated with expression of ETS. RNASET2 knockdown in T cells increased expression of IFNG and intercellular adhesion molecule 1 (ICAM1) and induced T-cell aggregation. A blocking antibody against (ILFA1), disrupting the lymphocyte function-associated antigen 1-intercellular adhesion molecule 1 interaction, reduced T-cell production of IFNG. CONCLUSIONS: We identified decreased expression of RNASET2 as a component of TL1A-mediated increase in production of IFNG and as a potential biomarker for patients with severe CD. Further study of the role of RNASET2 in regulating mucosal inflammation may lead to development of novel therapeutic targets.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Gonsky R, Fleshner P, Deem RL, et al. Association of Ribonuclease T2 Gene Polymorphisms With Decreased Expression and Clinical Characteristics of Severity in Crohn's Disease. Gastroenterology. 2017. PMID: 28400196. doi:10.1053/j.gastro.2017.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。